Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load
- PMID: 20736815
- DOI: 10.1097/QAD.0b013e32833e5043
Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load
Abstract
Objective: Few studies have assessed longitudinal genital tract HIV-1 shedding. We determined patterns of genital tract HIV-1 RNA shedding over time among women with suppressed plasma viral load (PVL) on antiretroviral treatment.
Methods: Paired plasma and genital tract HIV-1 RNA were measured every 4 weeks. Participants were classified as persistent, intermittent, or nonshedders. Longitudinal analysis examined rates of genital tract shedding and the association with PVL, CD4 cell count, and genital tract infections. Markov transition models were used to describe the dynamics of HIV-1 RNA in plasma and genital tract using visit-to-visit transitions from and to detectable and undetectable PVL or genital tract HIV-1 RNA.
Results: Fifty-nine women contributed 582 study visits of whom 95 and 98% had below-detectable PVL and genital tract viral load, respectively, at baseline. Thirty-two of 59 women (54%) had detectable HIV-1 RNA at least once in the genital tract. Twenty-two of 59 (37%) women had detectable genital tract HIV-1 RNA during a study visit when PVL was undetectable; 6.8% of the women were persistent shedders, 31% were intermittent shedders, and 45.8% were nonshedders. Sampling three subcompartments increased detection of HIV-1 genital tract viral load compared to sampling a single subcompartment. Overall, genital tract HIV-1 RNA shedding in any subcompartment occurred at about 13% of visits. Shedding in at least one of the three subcompartments occurred at 9% of visits when PVL was undetectable (95% confidence interval 6-14%).
Conclusion: Women with below-detectable PVL may have less risk of HIV sexual transmission on a population level, but may continue to be infectious on an individual level.
Comment in
-
Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load.AIDS. 2011 Mar 27;25(6):880-1. doi: 10.1097/QAD.0b013e328344ccf8. AIDS. 2011. PMID: 21412068 No abstract available.
Similar articles
-
Persistent genital tract HIV-1 RNA shedding after change in treatment regimens in antiretroviral-experienced women with detectable plasma viral load.J Womens Health (Larchmt). 2013 Apr;22(4):330-8. doi: 10.1089/jwh.2012.3849. Epub 2013 Mar 26. J Womens Health (Larchmt). 2013. PMID: 23531097 Free PMC article.
-
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies.AIDS. 2003 Oct 17;17(15):2169-76. doi: 10.1097/00002030-200310170-00004. AIDS. 2003. PMID: 14523273
-
Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding.J Acquir Immune Defic Syndr. 2012 May 1;60(1):99-110. doi: 10.1097/QAI.0b013e31824aeaaa. J Acquir Immune Defic Syndr. 2012. PMID: 22517416 Free PMC article.
-
Recent observations on HIV type-1 infection in the genital tract of men and women.AIDS. 2003 Mar 7;17(4):455-80. doi: 10.1097/00002030-200303070-00001. AIDS. 2003. PMID: 12598766 Review. No abstract available.
-
Detection of human immunodeficiency virus type 1 and type 2 in the female genital tract: implications for the understanding of virus transmission.Obstet Gynecol Surv. 1997 May;52(5):315-24. doi: 10.1097/00006254-199705000-00024. Obstet Gynecol Surv. 1997. PMID: 9140133 Review.
Cited by
-
Twelve-Month Antiretroviral Therapy Suppresses Plasma and Genital Viral Loads but Fails to Alter Genital Levels of Cytokines, in a Cohort of HIV-Infected Rwandan Women.PLoS One. 2015 May 26;10(5):e0127201. doi: 10.1371/journal.pone.0127201. eCollection 2015. PLoS One. 2015. PMID: 26010956 Free PMC article.
-
BRIEF - SYNOPSIS OF THE CURRENT EVIDENCE ON THE RISK OF HIV TRANSMISSION.Can Commun Dis Rep. 2013 Nov 29;39(1):9-16. doi: 10.14745/ccdr.v39i01a02. eCollection 2013 Nov 29. Can Commun Dis Rep. 2013. PMID: 31680696 Free PMC article.
-
HIV-DNA in the genital tract of women on long-term effective therapy is associated to residual viremia and previous AIDS-defining illnesses.PLoS One. 2013 Aug 21;8(8):e69686. doi: 10.1371/journal.pone.0069686. eCollection 2013. PLoS One. 2013. PMID: 23990886 Free PMC article.
-
Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum.J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):308-313. doi: 10.1097/QAI.0000000000001677. J Acquir Immune Defic Syndr. 2018. PMID: 29528944 Free PMC article.
-
Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS.Gene Ther. 2017 Jul;24(7):377-384. doi: 10.1038/gt.2017.35. Epub 2017 Jun 1. Gene Ther. 2017. PMID: 28471431 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials